MHRA submission follows EMA validation of the VIZZ MAA in March 2026
Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion
Read more at globenewswire.comLENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
Provided By GlobeNewswire – Last update: